CAJ | 학술논문

心房颤动(atrial fibrillation,AF)是卒中的独立危险因素.AF患者的卒中转归较差,致死率和致残率也较高.对于卒中风险较高的AF患者,需要应用抗凝药.阿哌沙班是近年来新出现的一种口服直接Xa因子抑制药.与华法林等传统抗凝药相比,阿哌沙班在预防AF患者卒中和全身性栓塞方面展现出一定的优势.
심방전동(atrial fibrillation,AF)시졸중적독립위험인소.AF환자적졸중전귀교차,치사솔화치잔솔야교고.대우졸중풍험교고적AF환자,수요응용항응약.아고사반시근년래신출현적일충구복직접Xa인자억제약.여화법림등전통항응약상비,아고사반재예방AF환자졸중화전신성전새방면전현출일정적우세.
Atrial fibrillation (AF) is an independent risk factors for stroke.The stroke outcome in patients with AF is poor.The mortality and morbidity were also higher.As for the higher risk of stroke in patients with AF,the application of anticoagulant drugs is needed.Apixaban is an emerging oral direct Ⅹ a factor inhibitor in recent years.Compared to the traditional anticoagulants,such as warfarin,apixaban shows certain advantages in the prevention of stroke and systemic embolism in patients with AF.